We used KRAS-driven murine PAN 02 and human L3.6pl pancreatic cancer cells to test the effectiveness of DFMO and GW5074 treatments at previously optimized concentrations [9,21,22], alone and in combination, to inhibit pancreatic tumor cell growth. Here, KRAS is linked to familial pancreatic carcinoma.